Since its discovery in 1984 by Svetlana Mosjov, GLP-1 and its analogs (such as semaglutide, liraglutide, and dulaglutide) have rapidly become cornerstone treatments for type 2 diabetes mellitus (T2DM) and obesity
They are also contraindicated or people with vision problems, Lebers disease, kidney failure, liver failure, folic acid deficiency or any type of systemic infection
This combination also produces short-chain fatty acids (SCFAs) in your colon, which further regulate hunger hormones
Anes J, McCusker MP, Fanning S, Martins M
Semaglutide Regulatory Status in Canada Health Canada Approval Status (Ozempic, Wegovy, Rybelsus, Generic) Semaglutide is the active ingredient in three Novo Nordisk products authorized for sale in Canada: Ozempic (authorized 2018 for type 2 diabetes, with an expanded indication in 2024 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes), Rybelsus (oral semaglutide tablets authorized for type 2 diabetes), and Wegovy (authorized 2021 for chronic weight management, with an expanded indication in 2024 to reduce the risk of non-fatal myocardial infarction, and a Notice of Compliance with Conditions issued in December 2025 for non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis)
